Cell Therapeutics [CTIC] 第3贴。..

jochen

卡帖卡的太严重了。。。。。

在这里开个新贴。。。

就快 2010 年了。。。。新年新希望。。。。

4月 23 倒数 开始。。。。

葉芬

我先來捧場。。。


也順便放上價錢。。


Cell Therapeutics, Inc. (Public, NASDAQTIC)

1.14 +0.09 (8.57%)
After Hours: 1.15 +0.01 (0.88%)
Dec 18, 7:57PM EST

kelvin234

4月 23 ctic什么日子哦

白面包

4月 23 ctic什么日子哦
kelvin234 发表于 21-12-2009 10:49 PM

    决定ctic股东大富大贵的日子。。。

fda 会在那天宣布pixantrone 是否通过。。

SUNNY仔

我拿着的5000X $1.8看来要放多几个月了....

jochen

我拿着的5000X $1.8看来要放多几个月了....
SUNNY仔 发表于 22-12-2009 12:23 AM

   
只要不倒。。。4月 一定 会 hit  1.80...(speculate)...

葉芬

22/12/09


Cell Therapeutics, Inc. (CTIC) - Keep an eye on CTIC, the stock is trading back over all three major moving average which is bullish. I will buy CTIC for a trade if it can break above $1.30 with volume.

nggeewai

so many menver buy ctic share here

fifi1985

我也是小小股东

jochen

1.34
+0.17 (14.53%)


昨晚突然 动了一下。。。。。

2月快来临。。。
4月  也接着  快 到了。。。。ctic 终于 可以  看看了。

m.i.k.e

又来 dilution............


http://www.rttnews.com/Content/QuickFacts.aspx?Node=B1&Id=1179541%20&Category=Quick%20Facts

软趴趴

RTTNews) -  Cell Therapeutics, Inc. (CTIC:  News ) announced that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee, or ODAC, will review the New Drug Application for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma.

At the ODAC meeting, committee members evaluate presentations of efficacy and safety data made by the pharmaceutical sponsor of the drug under review, FDA review staff, and occasionally third-party oncology experts in an open forum. Following the presentation, the committee members discuss questions posed by the Agency review staff and the meeting concludes with the committee voting on a recommendation to the FDA regarding approval.

葉芬

今早凌晨時要Post新消息出來，不過佳禮Server Down。。

希望這沖勁是 一路向上 。。。。。。

jochen

又来 dilution............
m.i.k.e 发表于 14-1-2010 09:44 AM

我还没买 票。。。。

dilute。。。。我还来得及。。。。买票上车。。。。


麦麦  身体可好？

葉芬

15/1/2010


Cell Therapeutics, Inc. (CTIC) - CTIC hit a high in afterhours trading Wednesday night at $1.46. The company then announced an equity offering which sent shares down to around $1.20. There is a presentation afterhours Thursday that could potentially move the stock. Keep an eye on CTIC.

葉芬

19/1/2010

Cell Therapeutics, Inc. (CTIC) - With CTIC, I am watching Thursday's high at $1.24. As soon as the stock breaks above $1.24, I will buy CTIC again.

葉芬

20/1/2010

Cell Therapeutics, Inc. (CTIC) - With CTIC, I am watching Thursday's high at $1.24. As soon as the stock breaks above $1.24, I will buy CTIC again.

@.@MiKeY@.@

Cell Therapeutics FDA Panel Primer: What You Need to Know to Be Ready Next Week

Luke Timmerman 2/3/10

Seattle-based Cell Therapeutics will find out in seven days whether it has a legitimate shot at getting a new cancer drug on the U.S. market. This company has a long and controversial history, and it is guaranteed to generate noise over the next week from stock market bulls and bears. So I figured it might be useful to gather some of the relevant facts in advance of this modern version of Roman theater, otherwise known as an FDA advisory panel.

The main event starts at 8 am Eastern time/5 am Pacific on February 10. That’s when the Oncologic Drugs Advisory Committee, a panel of cancer drug experts that advises the FDA, will gather in a suburban Washington, DC, hotel. There, they’ll hear testimony about, and likely vote on, Cell Therapeutics’ application to market pixantrone (Pixuvri) as a new therapy for patients with relapsed, aggressive forms of non-Hodgkin’s lymphoma. The FDA isn’t required to follow the public advice of its expert panels, although it usually does.

Cell Therapeutics (NASDAQ: CTIC) has survived more than one near-death experience in the past, and CEO Jim Bianco has described 2009 as a “tight-wire act.” So pretty much the whole farm is riding on this panel vote. The company, which ran down to less than a couple of weeks of cash at one point last year, doesn’t have any marketed products generating cash at the moment and nothing besides pixantrone with a legitimate shot at imminent FDA approval. Amazingly, it has burned through more than $1.4 billion of capital since its founding in 1991 without ever becoming profitable. Yet the company has been so prodigious at convincing investors to keep writing checks, and so popular with the fast-money crowd, that it now has an astonishing 574 million shares outstanding. That’s more than Celgene (NASDAQ: CELG), a profitable maker of blood cancer drugs, which has a market capitalization of $26 billion.

The question of little Cell Therapeutics, and whether it will ever get within hailing distance of profitability, really hinges on a single study of 140 patients that doctors review next week.

“We do expect U.S. approval,” Cell Therapeutics president Craig Phillips told investors on January 14, during a presentation at the JP Morgan Healthcare Conference in San Francisco.

Before diving into the nitty-gritty of the medical evidence, a little bit of business background is necessary. Cell Therapeutics obtained pixantrone in 2003 when it paid $236 million to acquire Italy-based Novuspharma. The drug is a modified form of an anthracycline chemotherapy. Anthracyclines are potent cell-killing agents commonly used in patients newly diagnosed with lymphomas. They can induce long-term remissions, but they also can cause heart failure if they are used more than once. Novuspharma designed pixantrone to have the cell-killing power of an anthracyline infusion, without damaging the heart.

If the treatment is approved, Cell Therapeutics officials estimate the company can tap into a market of about 10,000 U.S. patients each year who are on at least their third round of treatment for aggressive non-Hodgkin’s lymphoma. Cell Therapeutics uses Cephalon’s bendamustine (Treanda), which costs $44,000 per patient, as a comparable benchmark on price, Phillips told investors last month. Assuming Cell Therapeutics captures one-third of the patient population, pixantrone could generate about $150 million annually in U.S. sales. The FDA’s deadline to make a decision is April 23.

The FDA’s advisory panel meetings can dwell on the most arcane and tangential of scientific questions, but the ultimate question usually comes down to whether the panel thinks that the evidence presented for a drug is strong enough to show that the benefit outweighs the risk—or whether more proof from clinical trials is necessary. Adam Feuerstein, an influential biotech columnist of TheStreet.com, published his seven-point case on what he sees as the weak spots in the Cell Therapeutics application.

The 140-patient study on which Cell Therapeutics’ case heavily relies is known as Extend or PIX 301. This study randomly assigned patients to get pixantrone or the physician’s choice of another chemotherapy drug. The study’s main goal was to show the treatment could completely wipe out tumors. The study reached its goal, and the finding was statistically significant. About 20 percent of patients on pixantrone (14 out of 70) had a “complete response” compared with 5.7 percent (4 out of 70) who did that well in the control group.

What about side effects? Patients in the pixantrone group had higher rates of white blood depletion, known as neutropenia, with 41 percent reporting a severe case of that effect, compared with 19 percent in the control group, according to data presented in June at the American Society of Clinical Oncology. An even more severe form of that condition, febrile neutropenia, was found in 7.4 percent of pixantrone patients, compared with 3 percent in the comparison group. There were also more cases of severe cardiac disorders reported among patients who got pixantrone—8.8 percent on the drug, compared with 4.5 percent in the control group.

While cancer drugs are allowed to have greater side effects than a new pain reliever.

Cell Therapeutics is betting its future on winning FDA approval of a drug that looks effective for non-Hodgkin’s lymphoma, but now comes word that patients on the drug in a clinical trial had a higher number of heart problems than those in a control group.

The Seattle-based biotech (NASDAQ: CTIC) disclosed that important fact today on page 7 of its annual report filed with the Securities and Exchange Commission. The finding comes from a study of 140 patients, called Extend, that randomly assigned patients to get an experimental drug, pixantrone, or another chemotherapy drug. The study found pixantrone was effective at completely shrinking tumors for 20 percent of patients, compared with 5.7 percent in a control group, according to a company statement we reported on in November. But the effectiveness apparently came with a side effect. Five of the patients in the pixantrone group had “severe cardiac events,” compared with two in the control group, the company said today in the annual report.

Cell Therapeutics acquired pixantrone for $236 million back in June 2003, when it acquired Italy-based Novuspharma. The drug is a modified version of an anthracycline, and is supposed to be designed to be less toxic to the heart than other drugs in its class. Cell Therapeutics, which has been scrambling to cut costs and raise capital in a last-ditch bid to stay in business, says its strategy is to submit the results of the pixantrone trial in the first half of this year to the FDA. If the FDA decides to give this application an expedited six-month review, Cell Therapeutics could find out before the end of 2009 whether the drug is good enough to win approval. Yet the company says even after selling off its lone marketed drug, Zevalin, and cutting 28 percent of its domestic workforce, it still doesn’t have enough operating cash to run past May.

The higher incidence of heart problems shouldn’t harm Cell Therapeutics’ application to the FDA, says company spokesman Dan Eramian. The finding from the Extend study doesn’t demonstrate that the drug caused the heart problems, which could have been caused by other things, says Jack Singer, the company’s chief medical officer.

“The numbers are too small to be statistically significant,” Eramian says, meaning the side effect could have been due to chance, rather than the drug.

Pixantrone has been studied in more than 400 patients overall, many of whom had prior treatments that are toxic to the heart, and the drug’s “safety profile is about as good as one could hope for,” says Jack Singer, Cell Therapeutics’ chief medical officer, in an interview. He says the full results of the Extend study will be presented at the American Society of Clinical Oncology’s annual meeting, scheduled for late May and early June.

The heart problem appears to be the most serious, but it wasn’t the only side effect seen in the trial with pixantrone. The study found that patients on pixantrone had a higher risk of leucopenia and neutropenia, common side effects from chemotherapy drugs in which white blood cells get depleted and can make patients vulnerable to infections. Researchers, however, found few cases of severe neutropenia, vomiting, or diarrhea, the company said. “Overall, the incidence of serious side effects was similar between pixantrone and the control arm,” the company said.

Swiss drug giant Novartis has an option to enter into an exclusive worldwide license to develop and commercialize pixantrone, although it hasn’t yet chosen to exercise that option, Cell Therapeutics says. If Novartis exercises that option, Cell Therapeutics would get $7.5 million in a license fee, as much as $104 million in registration and sales related milestones, and a royalty on worldwide sales.

If Cell Therapeutics can get that $7.5 million milestone fee, that would represent about 3.5 months of operating cash, since its monthly cash spending rate has been cut down to about $2.1 million. The company cut 34 jobs, or about 28 percent of its workforce earlier this month, bringing its total staff down to about 88 employees. Cell Therapeutics also said last month it is closing its Italian branch, eliminating 62 jobs there.

jochen

快买。。。。。2月10日  judgement day....



开始 动了。。。。不要错过。。。。。。

@.@MiKeY@.@

Cell Therapeutics Options Show Record Bets on Drugmaker Retreat

By Jeff Kearns and Elizabeth Lopatto

Feb. 4 (Bloomberg) -- Options traders are making record bets that Cell Therapeutics Inc. will extend a decade-long plunge that wiped out 99.96 percent of its value as the drugmaker undergoes a Feb. 10 review by U.S. regulators on its experimental cancer therapy.

The number of outstanding puts giving the right to sell the stock has jumped ninefold in the last month to 193,642, lifting the ratio over bullish calls to the highest level since March 2007. Since June, the shares have slumped 44 percent to $1.18, down from a split-adjusted $2,940 at their October 2000 peak.

“A lot of people think it’s going to zero,” said Chris Rich, head options strategist at JonesTrading Institutional Services LLC in Chicago. “You have a study that’s totally in question. That’s the fear.”

Investors are making unprecedented bets against the company after pushing the stock down to as low as 5 cents last year on speculation that its cancer treatments don’t work. Seattle-based Cell Therapeutics has no drugs on the market and has never been profitable. As of December 31, 2008, it had accumulated a deficit of $1.3 billion, according to a regulatory filing.

Cell Therapeutics spokesman Dan Eramian didn’t respond to telephone calls or an e-mail seeking comment.

Regulators are evaluating Cell Therapeutics’ lead product candidate, a non-Hodgkin lymphoma drug called pixantrone. The treatment targets patients who have failed two or more previous therapies for the cancer.

Remission Rates

The shares surged 47 percent to $2.10 on July 1 after Cell Therapeutics said pixantrone increased the remission rate of patients with non-Hodgkin’s lymphoma. The drug showed significant increases in complete remission rates, overall response rates, percentage of patients whose response lasted four months or longer, and progression-free survival, the company said in a statement.

Options traders gauge expectations for how much an event may move a stock by comparing the share price to the cost of buying a “straddle,” which pairs the purchase of a call and a put. To break even on the Cell Therapeutics straddle, the shares must fall below about 20 cents or rise above $1.80 by expiration on Feb. 19, according to data compiled by Bloomberg.

The February $1 puts have an implied volatility of 532.09, while this month’s Standard & Poor’s 500 Index puts closest to the index level have an implied volatility of 17.84. Implied volatility, a measure of expected price swings, is the key gauge of options prices. The February $1 puts have the largest open interest of all options on the stock, accounting for almost half of all contracts to sell shares.

‘Large Move’

“People buying the puts are expecting a large move on the news,” said Scott Becker, a derivatives strategist at Jefferies Group Inc. in New York. He said investors are using options to bet on a retreat because the shares are almost impossible to borrow for a short sale. “There’s definitely demand to get short and people who can’t because of a lack of availability may be able to gain short access through the put purchases,” he said.

The proposed treatment, to be called Pixuvri, will be considered by an advisory committee of the U.S. Food and Drug Administration next week. About 66,000 people were diagnosed with non-Hodgkin lymphoma, and 19,500 people died of the disease in 2009, according to the National Cancer Institute.

“I don’t think the product is going to be approved and I don’t think the data submitted by the company will result in a positive recommendation from the committee,” said Ira Loss, a senior health policy analyst at Washington Analysis LLC. “The clinical data don’t support approval. There’s a lot of gray here, it’s not black or white.”

The FDA usually follows the recommendations of its advisory panels, although it isn’t required to. The agency is scheduled to make a ruling on the drug by April 23.